Equillium, Inc. (NASDAQ:EQ – Get Rating) was the recipient of a large growth in short interest in October. As of October 31st, there was short interest totalling 718,400 shares, a growth of 11.3% from the October 15th total of 645,400 shares. Approximately 4.1% of the company’s stock are short sold. Based on an average daily volume of 217,700 shares, the days-to-cover ratio is currently 3.3 days.
Wall Street Analysts Forecast Growth
EQ has been the subject of a number of recent analyst reports. SVB Leerink lowered their price objective on Equillium from $14.00 to $12.00 and set an “outperform” rating for the company in a research report on Thursday, September 8th. HC Wainwright raised their price objective on Equillium from $15.00 to $20.00 and gave the stock a “buy” rating in a research report on Tuesday, September 27th.
Equillium Stock Performance
Shares of EQ stock opened at $1.72 on Tuesday. The firm has a market capitalization of $58.95 million, a price-to-earnings ratio of -0.75 and a beta of 1.15. The company has a debt-to-equity ratio of 0.15, a current ratio of 3.98 and a quick ratio of 3.98. The business has a fifty day moving average of $1.98 and a 200 day moving average of $2.23. Equillium has a 1 year low of $1.56 and a 1 year high of $5.68.
Hedge Funds Weigh In On Equillium
Institutional investors have recently modified their holdings of the stock. Renaissance Technologies LLC purchased a new position in shares of Equillium during the 2nd quarter valued at about $34,000. Dimensional Fund Advisors LP acquired a new stake in shares of Equillium during the 3rd quarter valued at about $43,000. Jane Street Group LLC acquired a new stake in shares of Equillium during the 1st quarter valued at about $47,000. Virtu Financial LLC acquired a new stake in shares of Equillium during the 3rd quarter valued at about $54,000. Finally, State Street Corp grew its position in shares of Equillium by 13.2% during the 1st quarter. State Street Corp now owns 56,220 shares of the company’s stock valued at $177,000 after acquiring an additional 6,564 shares during the period. Hedge funds and other institutional investors own 36.86% of the company’s stock.
Equillium, Inc, a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company's lead product candidate is itolizumab (EQ001), a clinical-stage monoclonal antibody that targets the novel immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase Ib clinical trial for the treatment of asthma disease; and Phase Ib clinical trial for the treatment of and lupus nephritis.
- Get a free copy of the StockNews.com research report on Equillium (EQ)
- Wayfair Still Has Its Fair Share of Issues
- Why did NIO take a $581.11 million loss last quarter?
- Take Two Interactive Software Stock is Taking One Step Back
- This Mid-Cap Tech Stock Embodies Diversified Growth
- Is It Time To Take A Ride With Joby Aviation’s EV Innovations?
Receive News & Ratings for Equillium Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Equillium and related companies with MarketBeat.com's FREE daily email newsletter.